Phaseline

Companies › Loki Therapeutics

Loki Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lm-LLO-TT
Live attenuated Listeria monocytogenes-based immunotherapy expressing tetanus toxoid and l
–Phase 1Pancreas Cancer, Duct Cell AdenocarcinomaOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07828236Lm-LLO-TTPhase 1Pancreas Cancer, Duct Cell AdenocarcinomaOncologyOct 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.